트랜스티레틴 아밀로이드증 치료 시장 규모, 점유율, 성장 분석 : 약물 유형별, 질환 유형별, 용도별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Transthyretin Amyloidosis Treatment Market size was valued at USD 7.2 Billion in 2024 and is poised to grow from USD 8.2 Billion in 2025 to USD 23.23 Billion by 2033, growing at a CAGR of 13.9% during the forecast period (2026-2033).

The transthyretin amyloidosis treatment market is primarily driven by innovative disease-modifying therapies that shift focus from symptomatic care to altering disease progression. Current therapies emphasize methods like protein stabilization, RNA silencing, and replacement, making this market crucial as patients confront severe cardiac and neurological decline. Advances in diagnostics, including noninvasive cardiac imaging and genetic testing, enhance case identification, while approvals of therapies such as tafamidis and patisiran stimulate investment and development. The expanding diagnostic landscape fosters reliable detection and clinical benefits, encouraging adoption. Additionally, AI enhances drug discovery and patient stratification by improving target analysis and refining patient cohorts, thus reducing trial inefficiencies. These dynamics present opportunities for gene therapies and partnerships, broadening access to effective treatments in underserved regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Transthyretin Amyloidosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Transthyretin Amyloidosis Treatment Market Segments Analysis

Global transthyretin amyloidosis treatment market is segmented by drug type, disease type, application, route of administration, distribution channel, end user and region. Based on drug type, the market is segmented into Transthyretin Stabilizers, Gene Silencing Therapies, Monoclonal Antibodies, Supportive Therapies and Others. Based on disease type, the market is segmented into Hereditary ATTR Amyloidosis and Wild-Type ATTR Amyloidosis. Based on application, the market is segmented into Polyneuropathy, Cardiomyopathy and Mixed Manifestations. Based on route of administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Care Centers and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Transthyretin Amyloidosis Treatment Market

A key market driver for the global transthyretin amyloidosis (ATTR) treatment market is the increasing prevalence of the disease, which is often underdiagnosed due to its varied symptoms and complexity. Awareness and understanding of ATTR are improving among healthcare professionals and patients, resulting in more accurate diagnoses and a greater demand for effective treatments. Additionally, advancements in drug development and biotechnology have led to the introduction of novel therapies that significantly improve patient outcomes, further stimulating market growth. The rising focus on early detection and individualized treatment approaches is also propelling investment and innovation within the ATTR treatment landscape.

Restraints in the Global Transthyretin Amyloidosis Treatment Market

One of the key market restraints for the global transthyretin amyloidosis treatment market is the high cost of therapy and treatment options. These therapies, particularly innovative biologics and gene therapies, often come with significant price tags, which can limit accessibility for patients and healthcare systems, particularly in low to middle-income regions. Additionally, the complexity of diagnosing transthyretin amyloidosis can lead to delays in treatment initiation, discouraging investment from healthcare providers. This combination of high costs and diagnostic challenges might hinder market growth, as more patients struggle to obtain timely and effective treatments.

Market Trends of the Global Transthyretin Amyloidosis Treatment Market

The global market for Transthyretin Amyloidosis treatment is experiencing a notable shift driven by advances in precision diagnostics. Innovations in molecular diagnostics and biomarker profiling facilitate earlier and more accurate identification of the disease's phenotypes, which enhances the selection of tailored therapeutic approaches. This trend fosters collaboration among diagnostics companies, specialty healthcare centers, and pharmaceutical developers, resulting in improved treatment outcomes. Additionally, the integration of genetic testing into clinical pathways is reshaping patient care, making it more efficient and effective. As healthcare providers and payers increasingly adopt diagnostic-driven care models, the focus remains on optimizing outcomes while ensuring sustainable resource allocation throughout the patient journey.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Transthyretin Amyloidosis Treatment Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Transthyretin Stabilizers
• Gene Silencing Therapies
• Monoclonal Antibodies
• Supportive Therapies
• Others

Global Transthyretin Amyloidosis Treatment Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Hereditary ATTR Amyloidosis
• Wild-Type ATTR Amyloidosis

Global Transthyretin Amyloidosis Treatment Market Size by Application & CAGR (2026-2033)

• Market Overview
• Polyneuropathy
• Cardiomyopathy
• Mixed Manifestations

Global Transthyretin Amyloidosis Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Subcutaneous

Global Transthyretin Amyloidosis Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

Global Transthyretin Amyloidosis Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Care Centers
• Homecare Settings

Global Transthyretin Amyloidosis Treatment Market Size & CAGR (2026-2033)

• North America (Drug Type, Disease Type, Application, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Drug Type, Disease Type, Application, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Disease Type, Application, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Disease Type, Application, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Disease Type, Application, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Alnylam Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurimmune
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eidos Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arrowhead Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corino Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SOM Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akcea Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Innovative Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations